Cyclo Therapeutics (CYTH) Projected to Post Quarterly Earnings on Monday

Cyclo Therapeutics (NASDAQ:CYTH) is projected to issue its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.32 million for the quarter.

Cyclo Therapeutics Stock Performance

CYTH opened at $0.70 on Friday. Cyclo Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.79. The firm has a market cap of $23.04 million, a P/E ratio of -0.78 and a beta of -0.57. The business’s fifty day moving average is $0.79 and its 200-day moving average is $0.73.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.